Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel based Can-Fite BioPharma has reported that a confirmatory Phase IIb trial is now enrolling patients as part of the ongoing development of CF101 for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
The current study consists of the two dose groups that provided the best results in the previous trial, with a control group and a 12-weeks treatment period. The trial will use a tablet formulation for CF101 which was recently developed by company. The company estimates that trial enrollment will continue for the next six months and that study results will be available during the first quarter of 2009. Can-Fite has sufficient financial resources to complete this Phase IIb trial in parallel to other ongoing clinical trials.
Pnina Fishman, CEO of Can-Fite, said: “we are pleased with the progress in developing CF101, within the predetermined timelines, and are happy to conduct this trial using the tablet formulation, which is the planned end product for marketing, provided subsequent trials are successful.”